
WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising:

an alkylated cyclodextrin; and

a compound of formula (I):



(I)

wherein each of R_1 are independently selected from C_{1-10} alkyl, substituted C_{1-10} alkyl, $-NR^{10}R^{11}$, $-NR^{12}C(O)R^{13}$, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{2-10} alkynyl, substituted C_{2-10} alkynyl, C_{6-20} aryl; substituted C_{6-20} aryl, heteroaryl, heterocyclic, heterocyclooxy, heterocyclothio, heteroarylamino, heterocycloamino, C_{4-10} cycloalkyl, substituted C_{4-10} cycloalkyl, C_{4-10} cycloalkenyl, substituted C_{4-10} cycloalkenyl, cyano, halo, $-OR^{10}$, $-C(O)OR^{10}$, and $-S(O)_2R^{10}$;

x is an integer from 0 to 5;

y is an integer from 0 to 4;

R^2 is selected from hydrogen, C_{1-10} alkyl, substituted C_{1-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{2-10} alkynyl, substituted C_{2-10} alkynyl, C_{6-20} aryl, substituted C_{6-20} aryl, C_{4-10} cycloalkyl, substituted C_{4-10} cycloalkyl, C_{4-10} cycloalkenyl, and substituted C_{4-10} cycloalkenyl;

R^3, R^4, and R^5 are independently selected from hydrogen, C_{2-8} alkyl, substituted C_{2-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{2-10} alkynyl, substituted C_{2-10} alkynyl, C_{6-20} aryl, substituted C_{6-20} aryl, C_{4-10} cycloalkyl, substituted C_{4-10} cycloalkyl, C_{4-10} cycloalkenyl, and substituted C_{4-10} cycloalkenyl;

each R^6 is independently selected from hydrogen, C_{1-10} alkyl, substituted C_{1-10} alkyl, $NR^{10}R^{11}$, $-NR^{12}C(O)R^{13}$, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{2-10} alkynyl, substituted C_{2-10} alkynyl, C_{6-20} aryl, substituted C_{6-20} aryl, heteroaryl, heterocyclic,

heterocyclooxy, heterocyclothio, heteroarylamino, heterocycloamino, C_{4-10} cycloalkyl, substituted C_{4-10} cycloalkyl, C_{4-10} cycloalkenyl, substituted C_{4-10} cycloalkenyl, cyano, halo, $-OR^{10}$, $-C(O)OR^{10}$, $-S(O)R^{10}$, and $-S(O)_2R^{10}$;

R^{10} and R^{11} are independently selected from hydrogen, C_{1-10} alkyl, substituted C_{1-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{2-10} alkynyl, substituted C_{2-10} alkynyl, C_{6-20} aryl, substituted C_{6-20} aryl, C_{4-10} cycloalkyl, substituted C_{4-10} cycloalkyl, C_{4-10} cycloalkenyl, and substituted C_{4-10} cycloalkenyl;

R^{12} is selected from hydrogen, C_{1-10} alkyl, substituted C_{1-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{2-10} alkynyl, substituted C_{2-10} alkynyl, C_{6-20} aryl, substituted C_{6-20} aryl, C_{4-10} cycloalkyl, substituted C_{4-10} cycloalkyl, C_{4-10} cycloalkenyl, and substituted C_{4-10} cycloalkenyl; and


R^{13} is selected from hydrogen, C_{1-10} alkyl, substituted C_{1-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkenyl, C_{2-10} alkynyl, substituted C_{2-10} alkynyl, C_6-C_{10} aryl, substituted C_{6-20} aryl, C_{4-10} cycloalkyl, substituted C_{4-10} cycloalkyl, C_{4-10} cycloalkenyl, substituted C_{4-10} cycloalkenyl, $-CH_2$-$N(CH_2CH_3)_3^+$, and $-CH_2$-SO_3^-,

or a pharmaceutically acceptable salt thereof;

wherein the azo bond in the compound of formula (I) may be either cis or trans; and

wherein the molar ratio of cyclodextrin to compound of formula (I) is from 1:1 to 500:1.

2. The composition of claim 1, wherein the alkylated cyclodextrin has the structure of formula (II):



(II)

or pharmaceutically acceptable salts thereof, wherein p is 4, 5, or 6, and R_1 is independently selected at each occurrence from –OH and optionally substituted –O-C_1-C_8 alkyl, wherein at least one R_1 is an optionally substituted –O-C_1-C_8 alkyl.

~~3. The composition of any one of claims 1 to 2, wherein the average degree of substitution with optionally substituted –O-C_1-C_8 alkyl of all cyclodextrin molecules in the composition is between 4 and 9.~~


~~4. The composition of any one of claims 1 to 2, wherein the average degree of substitution with optionally substituted –O-C_1-C_8 alkyl of all cyclodextrin molecules in the composition is between 6.5 and 7.5.~~

~~5. The composition of any one of claims 2 to 4, wherein at least one R_1 is O-(C_2-C_8 alkylene)-SO_3^- T, wherein T is independently selected at each occurrence from pharmaceutically acceptable cations.~~

~~6~~3. The composition of claim 2 ~~any one of claims 2 to 4~~, wherein at least one R_1 is –O-C_1-C_8 alkyl substituted with hydroxy.

~~7. The composition of any one of claims 2 to 6, wherein p is 5.~~


~~8~~4. The composition of claim 1, wherein the cyclodextrin has the structure of formula (III):





(III)

wherein each R is independently -H or -$(CH_2)_4$-$SO_3^-Na^+$, and the average degree of substitution with –$(CH_2)_4$-$SO_3^-Na^+$ of all cyclodextrin molecules in the composition is from 6 to 7.1.


~~9~~5. The composition of claim 1, wherein the compound of formula (I) is selected from the group consisting of:










(







(QAQ)












(BEAAQ)






(7.72)




(7.73)



and


(7.75)



(7.76)

or pharmaceutically acceptable salts thereof, wherein the azo bond in the compounds of formula (I) may be either cis or trans.

~~10. The composition of any one of claims 1 to 8, wherein the compound of formula (I) has the structure:~~



~~or a pharmaceutically acceptable salt thereof, wherein the azo bond in the structure may be either cis or trans.~~

~~11~~6. The composition of any one of claims 1 to ~~10~~ 5, wherein the molar ratio of cyclodextrin to compound of formula (I) is from 2:1 to 350:1.

~~12~~7. The composition of any one of claims 1 to ~~10~~ 5, wherein the molar ratio of cyclodextrin to compound of formula (I) is from 3:1 to 150:1.

~~13~~8. The composition of any one of claims 1 to ~~12~~ 7, wherein the concentration of the compound of formula (I) is from 50 µM to 200 µM.

~~14. The composition of any one of claims 1 to 12, wherein the concentration of the compound of formula (I) is from 75 µM to 150 µM.~~

~~15~~9. The composition of any one of claims 1 to ~~12~~ 5, wherein the concentration of the compound of formula (I) is about 100 µM.

~~16~~10. The composition of any one of claims 1 to ~~15~~ 9, wherein the azo bond in greater than 50% of molecules of formula (I) in the composition is trans.

~~17. The composition of any one of claims 1 to 15, wherein the azo bond in greater than 70% of molecules of formula (I) in the composition is trans.~~

~~18. The composition of any one of claims 1 to 15, wherein the azo bond in greater than 90% of molecules of formula (I) in the composition is trans.~~

~~19. The composition of any one of claims 1 to 15, wherein the azo bond in greater than 95% of molecules of formula (I) in the composition is trans.~~

~~20. The composition of any one of claims 1 to 15, wherein the azo bond in greater than 50% of molecules of formula (I) in the composition is cis.~~

~~21. The composition of any one of claims 1 to 15, wherein the azo bond in greater than 70% of molecules of formula (I) in the composition is cis.~~

~~22. The composition of any one of claims 1 to 15, wherein the azo bond in greater than 90% of molecules of formula (I) in the composition is cis.~~

~~23. The composition of any one of claims 1 to 15, wherein the azo bond in greater than 95% of molecules of formula (I) in the composition is cis.~~

~~24~~11. The composition of any one of claims 1 to ~~15~~ 9, wherein greater than 50% of the molecules of formula (I) in the composition are complexed with the cyclodextrin.

~~25. The composition of any one of claims 1 to 15, wherein greater than 70% of the molecules of formula (I) in the composition are complexed with the cyclodextrin.~~

12~~26~~. The composition of any one of claims 1 to ~~15~~ 9, wherein greater than 90% of the molecules of formula (I) in the composition are complexed with the cyclodextrin.

~~27. The composition of any one of claims 1 to 15, wherein greater than 95% of the molecules of formula (I) in the composition are complexed with the cyclodextrin.~~

~~28. The composition of any one of claims 1 to 15, wherein less than 50% of the molecules of formula (I) in the composition are complexed with the cyclodextrin.~~

~~29. The composition of any one of claims 1 to 15, wherein less than 30% of the molecules of formula (I) in the composition are complexed with the cyclodextrin.~~

~~30. The composition of any one of claims 1 to 15, wherein less than 10% of the molecules of formula (I) in the composition are complexed with the cyclodextrin.~~

~~31~~13. The composition of any one of claims 1 to ~~30~~ 12, further comprising a buffer.

~~32~~14. The composition of any one of claims 1 to ~~31~~ 13, wherein the composition is an aqueous solution, and~~.~~

~~33. The composition of any one of claims 1 to 31, wherein~~ the solution has an osmolality between 250 mOsm and 350 mOsm.

~~34~~15. The composition of any one of claims 1 to ~~31~~ 13, wherein the composition is a solid suitable for reconstitution.

~~35~~16. ~~A method of treating a retinal disorder, comprising injecting the~~ Use of a composition of any one of claims 1 to ~~33~~ 14 in the manufacture of a medicament for treating a ~~into the vitreous of a subject having the~~ retinal disorder.

~~36~~17. The ~~method~~ use of claim ~~35~~ 16, wherein the retinal disorder is retinitis pigmenosa or age-related macular degeneration.

~~37~~18. The ~~method~~ use of any one of claims ~~35~~ 16 to ~~36~~ 17, comprising prior to said injection, exposing the composition to light.

~~38~~19. The ~~method~~ use of claim ~~37~~ 18, wherein the light comprises light having a wavelength of 350 nm to 500 nm.

~~39~~20. The ~~method~~ use of any one of claims ~~37~~ 18 to ~~38~~ 19, wherein the composition is exposed to from 200 J/ml to 2000 J/ml of 350 nm to 500 nm light.